- Home
- ATAT vs CELC Comparison
ATAT vs CELC Comparison
Compare ATAT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAT | CELC |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.2B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ATAT | CELC |
|---|---|---|
| Price | $34.33 | $89.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $49.00 | ★ $112.56 |
| AVG Volume (30 Days) | 750.4K | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.48 | N/A |
| Revenue Next Year | $18.11 | $720.19 |
| P/E Ratio | $26.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.78 | $44.42 |
| 52 Week High | $43.17 | $151.02 |
Technical Indicators
Market Signals| Indicator | ATAT | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 45.85 |
| Support Level | $31.27 | $82.48 |
| Resistance Level | $35.84 | $117.54 |
| Average True Range (ATR) | 0.93 | 4.23 |
| MACD | 0.17 | 1.03 |
| Stochastic Oscillator | 65.12 | 69.68 |
Price Performance
Historical ComparisonAbout ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.